DelMar Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. Our lead product candidate, VAL-083, is a "first-in-class" small molecule DNA-targeting agent that is currently being evaluated in a biomarker-driven Phase 2 clinical trial for the treatment of Unmethylated MGMT recurrent glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. We are also exploring VAL-083 in a Phase 2 trial as a therapy for front-line Unmethylated MGMT GBM and we may study other solid tumors, including ovarian cancer and pediatric CNS tumors. Source
No articles found.
Equillium is a biotechnology company leveraging deep understanding of immunobiolog...
Equillium is a biotechnology company leveraging...
ViewRayÂŽ Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdianÂŽ the wor...
ViewRayÂŽ Inc., (NASDAQ:VRAY), designs, manufac...
Artelo Biosciences is a biopharmaceutical company dedicated to applying true bioph...
Artelo Biosciences is a biopharmaceutical compa...
Alpine is a development-stage specialty pharmaceutical company focused on discover...
Alpine is a development-stage specialty pharmac...
Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug p...
Enlivex is a clinical stage immunotherapy compa...
JanOne, formerly Appliance Recycling Centers of America, Inc., and subsidiaries, i...
JanOne, formerly Appliance Recycling Centers of...
Kazia Therapeutics is an oncology-focused biotechnology company, developing innova...
Kazia Therapeutics is an oncology-focused biote...
Join the National Investor Network and get the latest information with your interests in mind.